Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice
Author(s)
Spencer, Alexandra J
McKay, Paul F
Belij-Rammerstorfer, Sandra
Ulaszewska, Marta
Bissett, Cameron D
Type
Journal Article
Abstract
Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities. Here, we present a detailed description of the immune response, in mice, following vaccination with a self-amplifying RNA (saRNA) vaccine and an adenoviral vectored vaccine (ChAdOx1 nCoV-19/AZD1222) against SARS-CoV-2. We demonstrate that antibody responses are higher in two-dose heterologous vaccination regimens than single-dose regimens. Neutralising titres after heterologous prime-boost were at least comparable or higher than the titres measured after homologous prime boost vaccination with viral vectors. Importantly, the cellular immune response after a heterologous regimen is dominated by cytotoxic T cells and Th1+ CD4 T cells, which is superior to the response induced in homologous vaccination regimens in mice. These results underpin the need for clinical trials to investigate the immunogenicity of heterologous regimens with alternate vaccine technologies.
Date Issued
2021-05-17
Date Acceptance
2021-04-19
Citation
Nature Communications, 2021, 12 (1)
ISSN
2041-1723
Publisher
Nature Research
Journal / Book Title
Nature Communications
Volume
12
Issue
1
Copyright Statement
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/34001897
PII: 10.1038/s41467-021-23173-1
Subjects
Animals
Antibodies, Neutralizing
Antibodies, Viral
COVID-19
COVID-19 Vaccines
Immunization, Secondary
Immunogenicity, Vaccine
Mice
RNA, Viral
SARS-CoV-2
Spike Glycoprotein, Coronavirus
T-Lymphocytes, Cytotoxic
Th1 Cells
Vaccination
Vaccines, Synthetic
Publication Status
Published
Coverage Spatial
England
Article Number
ARTN 2893